Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  European Heart Journal

• Publication date

  2008-09-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurheartj/ehp041PMID 19193675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

  2008cited by this paper
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

  2008cited by this paper
• Pharmacokinetics of clopidogrel in patients with stent thrombosis

  2008cited by this paper
• Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

  2008cited by this paper
• The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

  2008cited by this paper
• Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

  2008cited by this paper
• Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

  2007cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events

  2007cited by this paper
• Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

  2007cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients

  2007cited by this paper
• Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

  2007cited by this paper
• Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions

  2007cited by this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention).

  2006cited by this paper
• Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

  2006cited by this paper
• Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

  2006cited by this paper
• Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

  2006cited by this paper
• Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel

  2006cited by this paper
• ACC/AHA/SCAI Practice Guidelines, February 21, 2006

  2006cited by this paper
• Stent thrombosis is associated with an impaired response to antiplatelet therapy.

  2005cited by this paper
• Variability in platelet responsiveness to clopidogrel among 544 individuals.

  2005cited by this paper
• Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.

  2005cited by this paper
• A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite

  2005cited by this paper
• Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance

  2004cited by this paper
• A randomized trial comparing phosphorylcholine‐coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries

  2004cited by this paper
• Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel

  2004cited by this paper
• A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

  2004cited by this paper
• Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

  2001cited by this paper
• Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.

  2001cited by this paper
• Identification of the platelet ADP receptor targeted by antithrombotic drugs

  2001cited by this paper
• Identification and Biological Activity of the Active Metabolite of Clopidogrel

  2000cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper

• Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes—Pharmacogenomic Impact on Inter‐Organ Communication

  2025influential citation
• Evolution of coronary stents: innovations, antithrombotic strategies and future directions

  2025cites this paper
• Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

  2024cites this paper
• Pharmacokinetics and Bioequivalence of a Generic Ticagrelor 90‐mg Formulation Versus the Innovator Product in Healthy White Subjects Under Fasting Conditions

  2024cites this paper
• Effect of loss-of-function CYP2C19 variants on clinical outcomes in coronary artery disease patients treated with clopidogrel: A systematic meta-analysis approach.

  2024cites this paper
• Mad honey disease: A challenging encounter in the emergency department

  2024cites this paper
• Role of genetic polymorphisms in clopidogrel response variability: a systematic review

  2023cites this paper
• CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel

  2023cites this paper
• The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study

  2023influential citation
• Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy

  2023cites this paper
• Predictors of Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention

  2023cites this paper
• Genetic Polymorphism of CYP2C19 in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (PCI) in Erbil

  2022cites this paper
• Personalized antiplatelet therapy in patients with coronary artery disease: past, present and future

  2022cites this paper
• Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients

  2022cites this paper
• CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

  2022cites this paper
• The Effect of Total Cholesterol Variability on Clinical Outcomes After Percutaneous Coronary Intervention

  2022cites this paper
• Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

  2022cites this paper
• CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).

  2022cites this paper
• Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art

  2022cites this paper
• The Cytochrome P450 2C19 Polymorphism is Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel.

  2022cites this paper
• CYP2C19 gene polymorphism and its impact on the long-term prognosis after myocardial infarction

  2022cites this paper
• CYP2C19 genotype has prognostic value in specific populations following coronary stenting

  2021cites this paper
• Guided P2Y12 inhibitor therapy after percutaneous coronary intervention.

  2021cites this paper
• Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.

  2021cites this paper
• ФАРМАКОГЕНЕТИЧЕСКИЕ ОСНОВЫ ИНДИВИДУАЛЬНОЙ ЧУВСТВИТЕЛЬНОСТИ И ПЕРСОНАЛИЗИРОВАННОГО НАЗНАЧЕНИЯ АНТИАГРЕГАНТНОЙ ТЕРАПИИ В РАЗЛИЧНЫХ ЭТНИЧЕСКИХ ГРУППАХ

  2021cites this paper
• PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS

  2021cites this paper
• Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis

  2021cites this paper
• POLIMORFISME CYP2C19*2 TERHADAP AGREGASI PLATELET DAN KEJADIAN KARDIOVASKULAR PADA PASIEN PENYAKIT JANTUNG KORONER

  2021cites this paper
• Differential Impact of Cytochrome 2C19 Allelic Variants on Three Different Platelet Function Tests in Clopidogrel-Treated Patients

  2021influential citation
• CYP2C19*2 genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel: a matched case-control study

  2021cites this paper
• Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.

  2020cites this paper
• Genetic Polymorphisms In Clopidogrel And Its Association With Adverse Cardiac Events After Coronary Intervention In Tertiary Care Centre From South India

  2020cites this paper
• Farmacogenômica e Doença Cardiovascular: Onde Estamos e Para Onde Vamos

  2020cites this paper
• The opioid-P2Y12 inhibitor interaction: Potential strategies to mitigate the interaction and consideration of alternative analgesic agents in myocardial infarction.

  2020cites this paper
• Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.

  2020cites this paper
• Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis

  2020cites this paper
• Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice

  2020cites this paper
• GENES and In-Stent Restenosis: Review

  2020cites this paper
• Pharmacogenetic testing: 5 Questions

  2020cites this paper
• Open-label multicenter registry on the outcomes of peripheral arterial disease treated by balloon angioplasty with optical frequency domain imaging in superficial femoral artery and popliteal artery (OCEAN-SFA study)

  2020cites this paper
• Genetic predisposition for the development of complications in patients after coronary artery stenting

  2020cites this paper
• Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial

  2020cites this paper
• Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.

  2020cites this paper
• Cytochrome p450 and VKORC1 Genotyping for Treatment Selection and Dosing

  2019cites this paper
• Cytochrome P 450 Genotyping Policy Number : 2 . 04 . 38 Last Review : 3 / 2019 Origination : 3 / 2017 Next Review : 3 / 2020 Policy

  2019cites this paper
• Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

  2019cites this paper
• Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects

  2019cites this paper
• Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

  2019cites this paper
• Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy

  2019cites this paper
• Antiplatelet Therapy in Cardiovascular Medicine

  2019cites this paper
• Influence of CYP2C19 Phenotype on the Effect of Clopidogrel in Patients Undergoing a Percutaneous Neurointervention Procedure

  2019cites this paper
• Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation

  2019cites this paper
• The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention

  2019cites this paper
• Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome

  2019cites this paper
• Biomarkers for Antiplatelet Therapy

  2019cites this paper
• Farmacogenética del clopidogrel en pacientes sometidos a neurointervención percutánea

  2019influential citation
• Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.

  2019cites this paper
• Pharmacogenetics in Cardiovascular Diseases

  2019cites this paper
• Triple Antithrombotic Therapy with Direct Oral Anticoagulants Versus Warfarin after Percutaneous Coronary Intervention with Genotyping

  2019cites this paper
• Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.

  2019cites this paper
• Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy

  2019cites this paper
• P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis

  2018cites this paper
• A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients

  2018cites this paper
• Impact of adenosine A2a receptor polymorphism rs5751876 on platelet reactivity in ticagrelor treated patients

  2018cites this paper
• The Prognostic Value of Combinations of Genetic Polymorphisms in the ITGB3, ITGA2, and CYP2C19*2 Genes in Predicting Cardiovascular Outcomes After Coronary Bypass Grafting

  2018cites this paper
• The individualized antiplatelet therapy following percutaneous coronary intervention : a case report and literature review

  2018cites this paper
• Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel

  2018cites this paper
• Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.

  2018cites this paper
• Ivabradine as adjuvant treatment for chronic heart failure.

  2018cites this paper
• Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.

  2018cites this paper
• The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes

  2018cites this paper
• Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy

  2018cites this paper
• Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions 

  2018cites this paper
• Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH

  2018cites this paper
• Continuum of Care for Acute Coronary Syndrome

  2018cites this paper
• Association of Gene Polymorphisms in CYP2C19, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients undergoing percutaneous coronary intervention

  2018cites this paper
• Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?

  2018cites this paper
• [Possible Genetic Predictors of Cardiovascular Complications After Coronary Artery Bypass Surgery].

  2018influential citation
• CYP2C19 Genotyping in Percutaneous Coronary Intervention-Treated Patients: Ready for Prime Time?

  2018cites this paper
• Cytochrome p450 and VKORC1 Genotyping for Treatment Selection and Dosing

  2018cites this paper
• Role of genetic testing in patients undergoing percutaneous coronary intervention

  2018cites this paper
• Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?

  2018cites this paper
• CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention

  2018cites this paper
• Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

  2017cites this paper
• PRELIMINARY DATA FROM A STUDY ON POLYMORPHISM RS 4244285 OF P 4502 C 19 CYTOCHROME GENE IN PATIENTS WITH ACUTE CORONARY SYNDROME , UNDERGOING TREATMENT WITH DUAL ANTIPLATELET THERAPY WITH CLOPIDOGREL AND ASPIRIN ReviewOriginal

  2017cites this paper
• Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.

  2017cites this paper
• Association of polymorphisms Gene CYP2C19 with endpoints of efficacy and safety of clopidogrel therapy And platelet aggregation in patients with acutecoronary syndrome study Protocol

  2017cites this paper
• Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

  2017cites this paper
• Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents.

  2017cites this paper
• Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.

  2017cites this paper
• Resultados de la terapia antiagregante guiada por genotipado de los polimorfismos en los genes cyp2c19 y abcb1 en pacientes sometidos a intervención coronaria percutánea con stent

  2017cites this paper
• Personalized Medicine for Coagulopathies

  2017cites this paper
• [The role of -omics technology in the pathophysiology, diagnosis, and treatment of cardiovascular diseases].

  2017cites this paper
• Platelets and Polymorphisms

  2017cites this paper
• Platelet distribution width as the prognostic marker in coronary bifurcation treatment

  2017cites this paper
• Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.

  2017cites this paper
• Cytochrome p 450 Genotyping 1 Cytochrome p 450 Genotyping Policy

  2017cites this paper
• Genetics in the Clinical Decision of Antiplatelet Treatment.

  2017cites this paper
• Thrombosis and haemostasis : Biological considerations and pharmacological issues

  2017cites this paper
• Identifying clinically relevant sources of variability: The clopidogrel challenge

  2017cites this paper